Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis

by Zacks Equity Research

Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

by Zacks Equity Research

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Medpace (MEDP) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

Medpace (MEDP) closed the most recent trading day at $395.95, moving +0.52% from the previous trading session.

QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays

by Zacks Equity Research

QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.

STERIS (STE) Gains From New Offerings, Macro Issues Ail

by Zacks Equity Research

STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial

by Zacks Equity Research

BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.

Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi

by Zacks Equity Research

Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.

Thermo Fisher's (TMO) New Launch Supports Full Lab Automation

by Zacks Equity Research

Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.

Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance

by Zacks Equity Research

Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.

Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Neogen's (NEOG) MDS Secures New Contract From USDA FSIS

by Zacks Equity Research

Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.

Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

by Zacks Equity Research

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

by Zacks Equity Research

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.

Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark

by Zacks Equity Research

Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

by Zacks Equity Research

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

Charles River (CRL) Partners to Reduce Animal Research Usage

by Zacks Equity Research

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

The latest trading day saw Medpace (MEDP) settling at $405.68, representing a +1.12% change from its previous close.

Align Technology (ALGN) Gains From New Alliances, Global Growth

by Zacks Equity Research

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data

by Zacks Equity Research

Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.

QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform

by Zacks Equity Research

QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

by Zacks Equity Research

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Nalak Das headshot

5 Growth Stocks to Buy for Steady Returns in June

by Nalak Das

We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are: APP, DDOG, MNDY, MEDP, WING.

Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes

by Zacks Equity Research

For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.

ICON (ICRL) Gains From Strategic Acquisitions, Innovation

by Zacks Equity Research

In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.